Shibata T, Iwai N, Miyazaki M, Kawamura Y, Kodama T
Research Laboratories, Toyama Chemical Co., Ltd., Japan.
Jpn J Antibiot. 1995 Jun;48(6):878-85.
Antigenicity studies of T-3761, a new quinolone derivative, were conducted and the following results were obtained. 1. By active systemic anaphylaxis test in guinea pigs, neither immunogenicity nor allergenicity of T-3761 was noted. 2. By homologous 4-hour passive cutaneous anaphylaxis (PCA) test using the serum obtained from these guinea pigs, neither immunogenicity nor allergenicity of T-3761 was noted. 3. The potential of IgE antibody production in mice was examined by heterologous 24-hour PCA test in rats. But neither the potential of IgE antibody production nor allergenicity of T-3761 was noted. 4. By passive hemagglutination assay, we analysed the antibody titer in rats and dogs serum obtained from three-month toxicity repeated dose studies (oral and intravenously administration). But the hemagglutination response was negative and specific antibodies were not detected.
对新型喹诺酮衍生物T-3761进行了抗原性研究,结果如下:1. 通过豚鼠主动全身过敏试验,未发现T-3761具有免疫原性或致敏性。2. 使用从这些豚鼠获得的血清进行同源4小时被动皮肤过敏(PCA)试验,未发现T-3761具有免疫原性或致敏性。3. 通过大鼠异源24小时PCA试验检测了小鼠产生IgE抗体的潜力。但未发现T-3761具有产生IgE抗体的潜力或致敏性。4. 通过被动血凝试验,我们分析了从为期三个月的毒性重复剂量研究(口服和静脉给药)获得的大鼠和犬血清中的抗体滴度。但血凝反应为阴性,未检测到特异性抗体。